COVID-19 Evidence Alerts from McMaster PLUSTM
Current best evidence for clinical care
(more info )
Looking for COVID vaccine articles?
Use our filters to search by PICO (population, intervention, comparator, outcome) and/or gender/race.
Loading articles...
PICO Filter
adolescent
adult
alpha; B.1.1.7; variant of concern; VOC
autoimmune patients
B.11.28
B.11.33
beta; B.1.351; variant of concern; VOC
BIPOC; Black, Indigenous, People of Colour
Breakthrough infection; post-vaccination COVID-19
cancer patients
children
chronic kidney disease
cirrhosis
close contacts, unvaccinated
close contacts, vaccinated
delta; B.1.617.2; variant of concern; VOC
diabetes
Epsilon (B.1.427; B.1.429)
gamma; P.1; variant of concern; VOC
health care workers (HCW)
healthy
hemodialysis
HIV
household contacts
immune mediated inflammatory disorders
immunocompromised
inborn errors of immunity
kidney transplant patients
long-term care (LTC) staff; long-term care facility (LTCF)
long-term care residents (LTC) residents; long-term care facility (LTCF)
non-responders
obese
omicron; B.1.1.529; variant of concern; VOC
Other inflammatory conditions
outbreak
pediatric
pregnant
previously infected
prison inmates
social care workers
surveillance
transplant
veterans
Zeta; P.2 lineage
Abdala; Center for Genetic Engineering and Biotechnology (CIGB); protein subunit vaccine
Ad5-nCoV; CanSino; Convidecia; non-replicating viral vector
Ad5-nCoV; non-replicating viral vector; AMMS
aluminum hydroxide
antibodies
ARCoV; mRNA vaccine
ARCT-021; LUNAR-COVID 19 vaccine; Arcturus Therapeutics Inc; RNA
Bactilis subtilis recombinant vaccine; oral
BICV;Biokangtai;inactivated adenovirus vaccine
BNT/BNT-28
BNT/ChA-28; heterologous
BNT162b1; Pfizer vaccine; mRNA
BNT162b2 primed with ChAdOx1-S; heterologous
booster; fourth dose
booster; third dose
ChAd/BNT-28; heterologous
ChAdOx-1-S primed with BNT162b2 booster
ChAdTS-S; AdC68-19S; viral vector vaccine
CIGB-66; Center for Genetic Engineering and Biotechnology; protein subunit
COH04S1; synthetic multiantigen modified ankara vaccine; City of Hope Medical Center
Comirnaty; Pfizer vaccine; BNT162b2; BioNTech/Fosun Pharma; mRNA
Corbevax; BECOV2A; protein subunit vaccine; Biological E Limited
CoV2 preS dTM; SARS-CoV-2 pre-fusion S protein; Sanofi Pasteur; adjuvant AF03 (Sanofi Pasteur) or AS03 (GlaxoSmithKline) or unadjuvanted
Covaxin vaccine; BBV152; Bharat Biotech; inactivated virus
COVID-19 Inactivated Vaccine; Shifa Pharmed Industrial Co; Inactivated
CovIran Vaccine
Covishield; SII-ChAdOx1 nCoV-19; Serum Institute of India; non-replicating viral vector
CoVLP; Medicago; virus-like particle
CVnCoV; Curevac; mRNA
DeINS1-nCoV-RBD LAIV; University of Hong Kong; replicating viral vector vaccine
delayed dose
EpiVacCorona vaccine; FBRI; protein subunit
FINLAY-FR-1A; SOBERANA Plus
Fiocruz vaccine;ChAdOx1-S1-S; inactivated vaccine
fully vaccinated
Gamaleya Research Institute; rAd5 and rAd26
GBP510; protein subunit vaccine; SK Bioscience Co Ltd: SKYCovione
genome sequencing
Group B meningococcal vaccine
GX-19; GX-19N; recombinant DNA vaccine;
Hepatitis A vaccine; Hep A vaccine
heterologous, prime-boost
IBM CAMS/Institute of Medical Biology; inactivated vaccine
influenza vaccine
INO-4800; Inovio; DNA vaccine
Johnson & Johnson vaccine; Janssen Pharmaceutical Companies; Ad26.COV2.S; non-replicating viral vector
KCONVAC/Shenzhen Kangtai Biological Products Co., Ltd
KCONVAC; Vero Cells; inactivated vaccine; Shenzhen Kangtai Biological Products
KoviVac; Chumakov Center; inactivated virus
MenACWY
meningococcal group A, C, W, and Y conjugate vaccine
MVC-COV1901; Medigen; protein subunit
Nanocovax; Nanogen; protein subunit vaccine
NDV-HXP-S; Butanvac; non-replicating vaccine; Newcastle disease virus
Noora; COVID-19 Recombinant RBD Protein vaccine; protein subunit vaccine; Bagheiat-allah University of Medical Sciences
Novavax vaccine; NVX-CoV2373; protein subunit
NSVI-06-08; CHO Cell; recombinant vaccine;
partially vaccinated
placebo
pneumococcal vaccine
QazVac; Kazakhstan RIBSP; inactivated
RQ3013; SARS-CoV-2 mRNA Chimera vaccine; Walvax Biotechnology; RNA
SARS-CoV-2 sclamp vaccine
SARS-CoV-2 Vaccine; Vero Cells; Minhai Biotechnology Co; inactivated
SCB-2019; Clover; protein subunit
SCoK; protein subunit vaccine; Zhongyianke Biotech Co. Ltd
Sf9 cells; recombinant vaccine; West China Hospital
Sinopharm vaccine; China National Biotec Group Company; Wuhan-WIV04; Beijing-HBO2; BBIBP-CorV; Vero Cells; inactivated virus
Sinovac vaccine; CoronaVac; inactivated virus
Soberana 02; FINLAY-FR-2; Instituto Finlay de Vacunas Cuba; protein subunit vaccine
Soberana Plus; FINLAY-FR-1A; Soberana booster; Instituto Finlay de Vacunas Cuba; protein subunit vaccine
Spikevax Bivalent Original/Omicron BA.1; mRNA-1273.214 vaccine; Moderna; RNA
Spikevax; Moderna vaccine; mRNA-1273 SARS-CoV-2; ModernaTX; mRNA
SpikoGen; Vaxine/CinnaGen Co.; protein subunit vaccine
Sputnick Light; Gamaleya; non-replicating viral vector
Sputnik V vaccine; Gam-COVID-Vac; non-replicating viral vector
TAK-919 (Moderna formulation); Takeda; mRNA
Tdap vaccine
Turkovac; ERUCOV-VAC; Health Institutes of Turkey; inactivated vaccine
unvaccinated
V-01; recombinant interferon-armed RBD dimer vaccine; fusion protein
V591/TMV-083, measles-vectored; live recombinant; vector-based
Vaxzevria; AstraZeneca vaccine; ChAd0x1 nCOV-19; non-replicating viral vector; adenovirus; University of Oxford/AstraZeneca; AZD1222
VLA2001; Valneva; vero-cell based; inactivated vaccine
ZF2001; Anhui Zhifei Longcom; protein subunit
ZR202-CoV; protein subunit vaccine
ZyCoV-D; Zydus Cadila; DNA
Abdala; Center for Genetic Engineering and Biotechnology (CIGB); protein subunit vaccine
Ad5-nCoV; CanSino; Convidecia; non-replicating viral vector
Ad5-nCoV; non-replicating viral vector; AMMS
aluminum hydroxide
antibodies
ARCoV; mRNA vaccine
ARCT-021; LUNAR-COVID 19 vaccine; Arcturus Therapeutics Inc; RNA
Bactilis subtilis recombinant vaccine; oral
BICV;Biokangtai;inactivated adenovirus vaccine
BNT/BNT-28
BNT/ChA-28; heterologous
BNT162b1; Pfizer vaccine; mRNA
BNT162b2 primed with ChAdOx1-S; heterologous
booster; fourth dose
booster; third dose
ChAd/BNT-28; heterologous
ChAdOx-1-S primed with BNT162b2 booster
ChAdTS-S; AdC68-19S; viral vector vaccine
CIGB-66; Center for Genetic Engineering and Biotechnology; protein subunit
COH04S1; synthetic multiantigen modified ankara vaccine; City of Hope Medical Center
Comirnaty; Pfizer vaccine; BNT162b2; BioNTech/Fosun Pharma; mRNA
Corbevax; BECOV2A; protein subunit vaccine; Biological E Limited
CoV2 preS dTM; SARS-CoV-2 pre-fusion S protein; Sanofi Pasteur; adjuvant AF03 (Sanofi Pasteur) or AS03 (GlaxoSmithKline) or unadjuvanted
Covaxin vaccine; BBV152; Bharat Biotech; inactivated virus
COVID-19 Inactivated Vaccine; Shifa Pharmed Industrial Co; Inactivated
CovIran Vaccine
Covishield; SII-ChAdOx1 nCoV-19; Serum Institute of India; non-replicating viral vector
CoVLP; Medicago; virus-like particle
CVnCoV; Curevac; mRNA
DeINS1-nCoV-RBD LAIV; University of Hong Kong; replicating viral vector vaccine
delayed dose
EpiVacCorona vaccine; FBRI; protein subunit
FINLAY-FR-1A; SOBERANA Plus
Fiocruz vaccine;ChAdOx1-S1-S; inactivated vaccine
fully vaccinated
Gamaleya Research Institute; rAd5 and rAd26
GBP510; protein subunit vaccine; SK Bioscience Co Ltd: SKYCovione
genome sequencing
Group B meningococcal vaccine
GX-19; GX-19N; recombinant DNA vaccine;
Hepatitis A vaccine; Hep A vaccine
heterologous, prime-boost
IBM CAMS/Institute of Medical Biology; inactivated vaccine
influenza vaccine
INO-4800; Inovio; DNA vaccine
Johnson & Johnson vaccine; Janssen Pharmaceutical Companies; Ad26.COV2.S; non-replicating viral vector
KCONVAC/Shenzhen Kangtai Biological Products Co., Ltd
KCONVAC; Vero Cells; inactivated vaccine; Shenzhen Kangtai Biological Products
KoviVac; Chumakov Center; inactivated virus
MenACWY
meningococcal group A, C, W, and Y conjugate vaccine
MVC-COV1901; Medigen; protein subunit
Nanocovax; Nanogen; protein subunit vaccine
NDV-HXP-S; Butanvac; non-replicating vaccine; Newcastle disease virus
Noora; COVID-19 Recombinant RBD Protein vaccine; protein subunit vaccine; Bagheiat-allah University of Medical Sciences
Novavax vaccine; NVX-CoV2373; protein subunit
NSVI-06-08; CHO Cell; recombinant vaccine;
partially vaccinated
placebo
pneumococcal vaccine
QazVac; Kazakhstan RIBSP; inactivated
RQ3013; SARS-CoV-2 mRNA Chimera vaccine; Walvax Biotechnology; RNA
SARS-CoV-2 sclamp vaccine
SARS-CoV-2 Vaccine; Vero Cells; Minhai Biotechnology Co; inactivated
SCB-2019; Clover; protein subunit
SCoK; protein subunit vaccine; Zhongyianke Biotech Co. Ltd
Sf9 cells; recombinant vaccine; West China Hospital
Sinopharm vaccine; China National Biotec Group Company; Wuhan-WIV04; Beijing-HBO2; BBIBP-CorV; Vero Cells; inactivated virus
Sinovac vaccine; CoronaVac; inactivated virus
Soberana 02; FINLAY-FR-2; Instituto Finlay de Vacunas Cuba; protein subunit vaccine
Soberana Plus; FINLAY-FR-1A; Soberana booster; Instituto Finlay de Vacunas Cuba; protein subunit vaccine
Spikevax Bivalent Original/Omicron BA.1; mRNA-1273.214 vaccine; Moderna; RNA
Spikevax; Moderna vaccine; mRNA-1273 SARS-CoV-2; ModernaTX; mRNA
SpikoGen; Vaxine/CinnaGen Co.; protein subunit vaccine
Sputnick Light; Gamaleya; non-replicating viral vector
Sputnik V vaccine; Gam-COVID-Vac; non-replicating viral vector
TAK-919 (Moderna formulation); Takeda; mRNA
Tdap vaccine
Turkovac; ERUCOV-VAC; Health Institutes of Turkey; inactivated vaccine
unvaccinated
V-01; recombinant interferon-armed RBD dimer vaccine; fusion protein
V591/TMV-083, measles-vectored; live recombinant; vector-based
Vaxzevria; AstraZeneca vaccine; ChAd0x1 nCOV-19; non-replicating viral vector; adenovirus; University of Oxford/AstraZeneca; AZD1222
VLA2001; Valneva; vero-cell based; inactivated vaccine
ZF2001; Anhui Zhifei Longcom; protein subunit
ZR202-CoV; protein subunit vaccine
ZyCoV-D; Zydus Cadila; DNA
adverse reactions; safety
all-cause death
allergy
anaphylaxis
anti-NTD, anti-N-terminal domain
anti-nucleocapsid protein IgG
anti-RBD IgG; anti-receptor-binding domain IgG
any infection
asymptomatic infection
breakthrough infection
COVID-related death
cycle threshold
genome sequencing
geometric mean titres
hospitalization
ICU admission; intensive care unit
immunogenicity
Long COVID; PASC (post-acute sequelae SARS-CoV-2 infection); post-COVID-19 condition
mild disease
moderate disease
neutralizing antibodies
reactogenicity
SARS-CoV-2 spike protein-binding antibodies
seroconversion
severe disease
severe, critical, or fatal disease
spike-specific T cell response
symptomatic infection
T-cell response
transmission
vaccine effectiveness
vaccine efficacy
VAERS; Vaccine Adverse Event Reporting System
waning over time
Demographic Filter
Female
Male
Non-binary
Not reported
Other
Black
Black -> African
Black -> Afro-Caribbean
Black -> African Canadian
Black -> African American
Black -> non-Hispanic Black
Asian
Asian -> East Asian
Asian -> East Asian -> Chinese
Asian -> East Asian -> Korean
Asian -> East Asian -> Japanese
Asian -> East Asian -> East Asian descent
Asian -> Southeast Asian
Asian -> Southeast Asian -> Vietnamese
Asian -> Southeast Asian -> Mongolian
Asian -> Southeast Asian -> Cambodian
Asian -> Southeast Asian -> Filipino
Asian -> Southeast Asian -> Singaporean
Asian -> Southeast Asian -> Indonesian
Asian -> Southeast Asian -> Malaysian
Asian -> Southeast Asian -> Taiwanese
Asian -> Southeast Asian -> Southeast Asian descent
Asian -> South Asian
Asian -> South Asian -> Afghan
Asian -> South Asian -> Pakistani
Asian -> South Asian -> Indian
Asian -> South Asian -> Bangladeshi
Asian -> South Asian -> Sri Lankan
Asian -> South Asian -> Indo-Caribbean
Asian -> South Asian -> South Asian descent
Indigenous
Indigenous -> First Nations
Indigenous -> Metis
Indigenous -> Inuk/Inuit descent
Indigenous -> Native American, American Indian
Indigenous -> Alaska Native
Indigenous -> Indigenous South American
Indigenous -> Native Hawaiian or other Pacific Islander
Indigenous -> Australian Aborigine
Hispanic
Latino
Latino -> Latin American
Middle Eastern
Middle Eastern -> Arab
Middle Eastern -> Persian
Middle Eastern -> Egyptian
Middle Eastern -> Iranian
Middle Eastern -> Lebanese
Middle Eastern -> Turkish
Middle Eastern -> Kurdish
Middle Eastern -> West Asian descent
Middle Eastern -> Israeli
White
White -> European descent
White -> Caucasian
White -> non-Hispanic white
Non-white
Multiracial
BIPOC
Not reported
Other
Keyword Filter